Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | IKBKB | O14920 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 1.00 |
| ▸ | BCL2 | P10415 | 1/20 | 1.00 |
| ▸ | TXN | P10599 | 1/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 1.00 |
| ▸ | SPTSSB | Q8NFR3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gambogic Acid SCHEMBL12751296 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL13685812 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12025387 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12025441 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12045553 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL24089082 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12026374 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL16160279 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL12045554 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 | |
| Gambogic Acid SCHEMBL13685811 | 1.00 | TP53 (1.00) | TP53MAPTMAPK1HSD17B10PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721758-A1 | NOVEL MEDICINE FOR TREATING OSTEOSARCOMA | Japanese Foundation For Cancer Research (JP) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024248045-A1 | NOVEL MEDICINE FOR TREATING OSTEOSARCOMA | 公益財団法人がん研究会 | 2024-12-05 | — | — | WO | disclosed |
| US-12064407-B2 | Endogenous retrovirus-k (ERVK) encodes an alternate envelope protein | UNIVERSITY OF WINNIPEG (CA) | 2024-08-20 | — | — | US | disclosed |
| US-11872220-B2 | Methods and compositions for treating B-cell malignancies | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20230064896-A1 | ENDOGENOUS RETROVIRUS-K (ERVK) ENCODES AN ALTERNATE ENVELOPE PROTEIN | UNIVERSITY OF WINNIPEG (CA) | 2023-03-02 | — | — | US | disclosed |
| US-7622497-B2 | Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090259054-A1 | Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration | THE TEXAS A&M UNIVERSITY SYSTEM | 2009-10-15 | — | — | US | disclosed |
| US-20070093456-A1 | Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2007-04-26 | — | — | US | disclosed |
| US-7176234-B2 | Anticancer agents; side effect reduction | CYTOVIA, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093456-A1 | Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis | BAD, BAX, CASP7 | TP53 162/4885MAPT 4755/4885MAPK1 953/4885 |
| US-11872220-B2 | Methods and compositions for treating B-cell malignancies | MALT1, BCL6, BCL3 | TP53 31/4885MAPT 1926/4885MAPK1 1977/4885 |
| US-20090259054-A1 | Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration | PDE6D, PDE6H, VEGFA | TP53 3159/4885MAPT 3618/4885MAPK1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.